POINT BIOPHARMA GLOBAL INC.

EDGAR

Market value is not computed: no listed ticker is recorded for this company.

18 filing records in this dataset, filed from 2020-06-15 to 2023-11-13. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

This issuer has insider filings in the store, but no transaction in this window or code group.

See all insider transactions

Latest quarter

Revenue

2.79 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating margin

-1,061.87%

2023 Q3 · %

Exact inputs and evidence
  • Operating Income: -29626162 USD Source
  • Revenue: 2789993 USD Source

Operating cash flow

-28.1 million USD

2023 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -124859499 USD Source
  • Operating Cash Flow: -96727236 USD Source

Free cash flow

-34.5 million USD

2023 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -124859499 USD Source
  • Operating Cash Flow: -96727236 USD Source
  • Capital Expenditure: 17249510 USD Source
  • Capital Expenditure: 10856112 USD Source
Cash and cash equivalents
21.6 million USD Source
Exact value

21607412 USD

Long-term debt including current maturities
Not available
Shares outstanding
106 million shares Source
Exact value

105765954 shares

Reported share-count change

1.64% · 1.71 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 104054962 shares · 2022-09-30· Source
  • 105765954 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

96.6 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence
  • Net income: 98293213 USD · 2022-01-01 – 2022-12-31 Source
  • Net income: -64973890 USD · 2022-01-01 – 2022-09-30 Source
  • Net income: -16530671 USD · 2023-01-01 – 2023-03-31 Source
  • Net income: -25410839 USD · 2023-04-01 – 2023-06-30 Source
  • Net income: -24774353 USD · 2023-07-01 – 2023-09-30 Source

Operating cash flow

112 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence
  • Operating cash flow: 183518622 USD · 2022-01-01 – 2022-12-31 Source
  • Operating cash flow: -53397277 USD · 2022-01-01 – 2022-09-30 Source
  • Operating cash flow: -22391341 USD · 2023-01-01 – 2023-03-31 Source
  • Operating cash flow: -96727236 USD · 2023-01-01 – 2023-06-30 Source
  • Operating cash flow: -22391341 USD · 2023-01-01 – 2023-03-31 Source
  • Operating cash flow: -124859499 USD · 2023-01-01 – 2023-09-30 Source
  • Operating cash flow: -96727236 USD · 2023-01-01 – 2023-06-30 Source

Capital expenditure

19.3 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence
  • Capital expenditure: 12766522 USD · 2022-01-01 – 2022-12-31 Source
  • Capital expenditure: 10696365 USD · 2022-01-01 – 2022-09-30 Source
  • Capital expenditure: 3524767 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 10856112 USD · 2023-01-01 – 2023-06-30 Source
  • Capital expenditure: 3524767 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 17249510 USD · 2023-01-01 – 2023-09-30 Source
  • Capital expenditure: 10856112 USD · 2023-01-01 – 2023-06-30 Source

Free cash flow

92.7 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence
  • Operating cash flow: 183518622 USD · 2022-01-01 – 2022-12-31 Source
  • Operating cash flow: -53397277 USD · 2022-01-01 – 2022-09-30 Source
  • Operating cash flow: -22391341 USD · 2023-01-01 – 2023-03-31 Source
  • Operating cash flow: -96727236 USD · 2023-01-01 – 2023-06-30 Source
  • Operating cash flow: -22391341 USD · 2023-01-01 – 2023-03-31 Source
  • Operating cash flow: -124859499 USD · 2023-01-01 – 2023-09-30 Source
  • Operating cash flow: -96727236 USD · 2023-01-01 – 2023-06-30 Source
  • Capital expenditure: 12766522 USD · 2022-01-01 – 2022-12-31 Source
  • Capital expenditure: 10696365 USD · 2022-01-01 – 2022-09-30 Source
  • Capital expenditure: 3524767 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 10856112 USD · 2023-01-01 – 2023-06-30 Source
  • Capital expenditure: 3524767 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 17249510 USD · 2023-01-01 – 2023-09-30 Source
  • Capital expenditure: 10856112 USD · 2023-01-01 – 2023-06-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-13.

Financial data available through: 2022-12-31.

Coverage by financial measure
  • Revenue: 2 of 11 periods available· newest 2022-12-31
  • Operating income: 3 of 11 periods available· newest 2022-12-31
  • Net income: 3 of 11 periods available· newest 2022-12-31
  • Operating cash flow: 3 of 11 periods available· newest 2022-12-31
  • Capital expenditure: 3 of 11 periods available· newest 2022-12-31
  • Total assets: 2 of 11 periods available· newest 2022-12-31
  • Total liabilities: 2 of 11 periods available· newest 2022-12-31
  • Current assets: 2 of 11 periods available· newest 2022-12-31
  • Current liabilities: 2 of 11 periods available· newest 2022-12-31
  • Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 2 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Revenue

    +USD 226.58 million

    Prior period

    USD 0

    –

    Current period

    USD 226.58 million

    –

    Exact inputs and evidence

    226579563 − 0 = 226579563 USD

    0 USD · 2021-01-01 – 2021-12-31

    Inspect prior input Prior source

    226579563 USD · 2022-01-01 – 2022-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Net income

    +USD 144.2 million

    Prior period

    −USD 45.9 million

    –

    Current period

    USD 98.29 million

    –

    Exact inputs and evidence

    98293213 − -45902481 = 144195694 USD

    -45902481 USD · 2021-01-01 – 2021-12-31

    Inspect prior input Prior source

    98293213 USD · 2022-01-01 – 2022-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 228.22 million

    Prior period

    −USD 44.7 million

    –

    Current period

    USD 183.52 million

    –

    Exact inputs and evidence

    183518622 − -44698758 = 228217380 USD

    -44698758 USD · 2021-01-01 – 2021-12-31

    Inspect prior input Prior source

    183518622 USD · 2022-01-01 – 2022-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    +45%

    Prior period

    USD 8.8 million

    –

    Current period

    USD 12.77 million

    –

    Exact inputs and evidence

    12766522 − 8802182 = 3964340 USD

    8802182 USD · 2021-01-01 – 2021-12-31

    Inspect prior input Prior source

    12766522 USD · 2022-01-01 – 2022-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

  • Revenue USD 226.58 million 100% of revenue
  • Operating costs Derived USD 101.06 million 45% of revenue
  • Operating income USD 125.52 million 55% of revenue
  • Tax, interest and other Derived USD 27.23 million 12% of revenue
  • Net income USD 98.29 million 43% of revenue

Cash

  • Operating cash flow USD 183.52 million 81% of revenue
  • Capital expenditure USD 12.77 million 5.6% of revenue
  • Free cash flow Derived USD 170.75 million 75% of revenue

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2021 Not shown: operating income or net income is not reported.
  • 2022 43%12%45%
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2021 2021-01-01 – 2021-12-310 45511830 Derived -45511830 390651 Derived -45902481 -53500940 Derived
Source
2022 2022-01-01 – 2022-12-31226579563 101057268 Derived 125522295 27229082 Derived 98293213 170752100 Derived
Source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 226.6M 2022
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.244.7M183.5M122.4M61.2M0.020212022
Values and sources
Revenue values and source evidence
PeriodSeriesValue(USD)Source evidence
2021Revenue0
2022Revenue226579563

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2021Year over yearNo prior comparable period
2022Year over yearNo prior comparable period

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 55.4% 2022
Net margin 43.4% 2022
Free cash flow margin 75.4% 2022
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.81%61%41%20%0%20212022
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2021Operating marginNot reported
2022Operating margin55.4%
2021Net marginNot reported
2022Net margin43.4%
2021Free cash flow marginNot reported
2022Free cash flow margin75.4%

Operating cash flow

Cash generated by the company’s normal business operations.

USD 183.5M 2022
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.201.8M135.6M69.4M3.2M-63.0M20212022
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2021Operating cash flow-44698758
2022Operating cash flow183518622

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 170.8M 2022
Free cash flow historyOperating cash flow minus capital expenditure for the same period and unit. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.188.7M123.7M58.6M-6.4M-71.4M20212022
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2021Free cash flow-53500940
2022Free cash flow170752100

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15.8% 2022
Liabilities to assets historyTotal liabilities as a share of total assets. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.17.1%12.8%8.5%4.3%0.0%20212022
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2021Liabilities / assets3.1%
2022Liabilities / assets15.8%

Current assets to current liabilities

Current assets divided by current liabilities.

6.66× 2022
Current assets to current liabilities historyCurrent assets divided by current liabilities. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.33.00×24.75×16.50×8.25×0.00×20212022
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2021Current assets / current liabilities30.56×
2022Current assets / current liabilities6.66×

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2020 2020-01-01 – 2020-12-31
−USD 13.37 million
Exact value

Exact value: -13373003 USD

2020-01-01 – 2020-12-31: -13373003 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 8.3 million
Exact value

Exact value: -8302856 USD

2020-01-01 – 2020-12-31: -8302856 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 9.8 million
Exact value

Exact value: 9797400 USD

2020-01-01 – 2020-12-31: 9797400 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 18.1 million
Calculation and evidence

-8302856 − 9797400 USD

Exact free cash flow: -18100256 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2021 2021-01-01 – 2021-12-31
−USD 45.9 million
Exact value

Exact value: -45902481 USD

2021-01-01 – 2021-12-31: -45902481 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 44.7 million
Exact value

Exact value: -44698758 USD

2021-01-01 – 2021-12-31: -44698758 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 8.8 million
Exact value

Exact value: 8802182 USD

2021-01-01 – 2021-12-31: 8802182 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 53.5 million
Calculation and evidence

-44698758 − 8802182 USD

Exact free cash flow: -53500940 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2022 2022-01-01 – 2022-12-31
USD 98.29 million
Exact value

Exact value: 98293213 USD

2022-01-01 – 2022-12-31: 98293213 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 183.52 million
Exact value

Exact value: 183518622 USD

2022-01-01 – 2022-12-31: 183518622 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 12.77 million
Exact value

Exact value: 12766522 USD

2022-01-01 – 2022-12-31: 12766522 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 170.75 million
Calculation and evidence

183518622 − 12766522 USD

Exact free cash flow: 170752100 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 965 latest values · 965 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001811764, 1811764, PNT, RACA, edgar:1811764, txac

Also known as POINT BIOPHARMA GLOBAL INC., POINT Biopharma Global Inc, POINT Biopharma Global Inc., Therapeutics Acquisition Corp.